K2 Investment Partners
VC Fund
Seoul, South Korea
K2 Investment Partners is a VC fund in Seoul focused on Biotechnology and Pharmaceutical. K2 Investment Partners is the first LLC to specialize in private equity secondary market in Korea, delivering liquidity solutions and risk-adjusted returns to investors. Since its establishment, K2 Investment has been dedicated to providing diversified and niche portfolios to investors and developing long-term relationships with investors andportfolio companies in the secondary market. We offer skills and experience that differentiate K2 Investment from other investment institutions. Our sophisticated analysis and superior deal sourcing network offer maximum risk-adjusted returns to our investors. Today, we are strenuously investing in variety of industries including electronics, software, chemistry, biotechnology, and medical devices.
- Total investments:
- 70
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries K2 Investment Partners invests in
Stages K2 Investment Partners invests in
Countries K2 Investment Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $2.9M–$11M
- Series B
- $7.1M–$39M
- Series C
- $12M–$33M
Investment Focus
Industry
- Biotechnology 13 (19%)
- Pharmaceutical 11 (16%)
- Software 10 (14%)
- Artificial Intelligence 9 (13%)
- Health Care 7 (10%)
Stage
- Series B 24 (34%)
- Series A 19 (27%)
- Series C 13 (19%)
- Venture - Series Unknown 4 (6%)
- Seed 2 (3%)
Country
- South Korea 52 (74%)
- United States 4 (6%)
- Japan 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bong Su
Co-Founder & Co-CEO
|
Co-Founder & Co-CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
6pence
|
6pence is a K-beauty skincare startup that develops skincare products for global consumers from the outset. | $1.4M / Seed / Aug 06, 2026 | |
Prazer Therapeutics
|
Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology. | $33.9M / Venture - Series Unknown / Jul 23, 2026 | |
BAT
|
BAT is developing an 'AI agent' utilizing its own algorithm and combining it with the integrated workspace 'AEer' to automate media operations. | $5.2M / Series A / Feb 03, 2026 | |
Logpresso
|
Logpresso (로그프레소) is a cyber security company, focusing on SecOps platforms. | $10.9M / Series B / Dec 16, 2025 | |
Typecast
|
Neosapience is a startup founded by former Qualcomm engineers and KAIST graduates in 2017. Their goal is to make AI powered virtual humans named Neosapience. They developed core technology to synthesize hyper-realistic and emotional speech from given text script. Currently, they run an AI voice actor service called Typecast based on the technology.Furthermore, they are also developing technologies to generate facial expressions and gestures, so that anyone can cast AI powered virtual voice and video actors and generate videos by just editing text. It would lead to a revolution in the media entertainment industry as creating content can be cheaper and easier. | $11.2M / Dec 09, 2025 | |
Playtag
|
Playtag operates an AI-based platform that uses behavioral analytics for early childhood education. The company develops learning tools for infants and toddlers and provides systems for kindergartens and daycare centers. These systems support the use of data-driven methods in teaching and classroom activities. | $4.4M / Venture - Series Unknown / Nov 25, 2025 | |
ADRO
|
Aerodynamic Hardware and Software Solutions | $6.9M / Series B / Nov 18, 2025 | |
Timetree
|
TimeTree keeps families and groups organized. It also helps manage busy lives while sharing calendars, events, and more! | $10.4M / Series F / Nov 05, 2025 | |
|
Timetree
|
TimeTree keeps families and groups organized. It also helps manage busy lives while sharing calendars, events, and more! | $10.4M / Secondary Market / Nov 05, 2025 | |
IMBiologics
|
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M / Series C / Oct 14, 2025 | |
| See all 70 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does K2 Investment Partners invest in?
K2 Investment Partners invests primarily in Biotechnology, Pharmaceutical and Software startups, most often at Series B and Series A stage. Most of the 70 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is K2 Investment Partners's check size?
K2 Investment Partners typically joins rounds of $2.9M–$11M at Series A, $7.1M–$39M at Series B and $12M–$33M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds K2 Investment Partners participates in.
How do I contact K2 Investment Partners?
Public channels for K2 Investment Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at K2 Investment Partners?
The team at K2 Investment Partners includes Bong Su (Co-Founder & Co-CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
